Literature DB >> 25868561

Prostate cancer: Sequencing AR-targeted agents might be ineffective in mCRPC.

Axel Heidenreich1, David Pfister1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25868561     DOI： 10.1038/nrurol.2015.81

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.

Authors:  Axel Heidenreich; David Pfister; Axel Merseburger; Georg Bartsch
Journal:  Eur Urol       Date:  2013-05-14       Impact factor: 20.096

2.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

3.  Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

Authors:  Guru Sonpavde; Gregory R Pond; William R Berry; Ronald de Wit; Andrew J Armstrong; Mario A Eisenberger; Ian F Tannock
Journal:  Urol Oncol       Date:  2010-10-02       Impact factor: 3.498

4.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

Review 5.  Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.

Authors:  Reinhard Buettner; Jürgen Wolf; Roman K Thomas
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

6.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

Review 7.  Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Authors:  Theodoros Karantanos; Christopher P Evans; Bertrand Tombal; Timothy C Thompson; Rodolfo Montironi; William B Isaacs
Journal:  Eur Urol       Date:  2014-10-08       Impact factor: 20.096

8.  Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.

Authors:  R J van Soest; A J Templeton; F E Vera-Badillo; F Mercier; G Sonpavde; E Amir; B Tombal; M Rosenthal; M A Eisenberger; I F Tannock; R de Wit
Journal:  Ann Oncol       Date:  2014-12-15       Impact factor: 32.976

9.  Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.

Authors:  Karim Fizazi; Christophe Massard; Matthew Smith; Michael Rader; Janet Brown; Piotr Milecki; Neal Shore; Stephane Oudard; Lawrence Karsh; Michael Carducci; Ronaldo Damião; Huei Wang; Wendy Ying; Carsten Goessl
Journal:  Eur Urol       Date:  2014-10-29       Impact factor: 20.096

10.  Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.

Authors:  H H Cheng; R Gulati; A Azad; R Nadal; P Twardowski; U N Vaishampayan; N Agarwal; E I Heath; S K Pal; H-T Rehman; A Leiter; J A Batten; R B Montgomery; M D Galsky; E S Antonarakis; K N Chi; E Y Yu
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-01-20       Impact factor: 5.554
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.